Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase

被引:42
作者
Anthony, NJ [1 ]
Gomez, RP
Schaber, MD
Mosser, SD
Hamilton, KA
O'Neil, TJ
Koblan, KS
Graham, SL
Hartman, GD
Shah, D
Rands, E
Kohl, NE
Gibbs, JB
Oliff, AI
机构
[1] Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA
[2] Merck Res Labs, Dept Canc Res, W Point, PA 19486 USA
关键词
D O I
10.1021/jm990080l
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Inhibitors of farnesyl protein transferase (FPTase) based upon a pseudotripeptide template are described that comprise an imidazole group substituted with a hydrophobic substituent. (1,5)-Disubstitution of the imidazole group is shown to be the optimal array that leads to potent and selective inhibitors of FPTase. A variety of aryl and isoprenyl substituents are shown to afford effective inhibitors, and the mechanism by which these compounds inhibit FPTase has been investigated. The biochemical. behavior of these compounds suggests that they bind to FPTase at the site usually occupied by the protein substrate. In experiments in cell culture, the methyl ester prodrugs of these inhibitors are cell permeant and potently inhibit the posttranslational modification of H-Ras protein. Additionally, these molecules revert the phenotype of ras transformed cells as evidenced by their ability to slow the growth of ras transformed cell lines in soft agar. One of the inhibitors, as its methyl prodrug, was evaluated in two in vivo models of tumor growth. The compound selectively inhibited the growth of tumors derived from H-ras transformed cells, in nude mice, and caused the regression of preexisting tumors in an H-ras transgenic animal model.
引用
收藏
页码:3356 / 3368
页数:13
相关论文
共 43 条
  • [1] BOS JL, 1989, CANCER RES, V49, P4682
  • [2] Potent, non-thiol inhibitors of farnesyltransferase
    Breslin, MJ
    deSolms, SJ
    Giuliani, EA
    Stokker, GE
    Graham, SL
    Pompliano, DL
    Mosser, SD
    Hamilton, KA
    Hutchinson, JH
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (23) : 3311 - 3316
  • [3] CLARK GJ, 1995, CELLULAR CANC MARKER, V320, P170
  • [5] COX AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51
  • [6] N-arylalkyl pseudopeptide inhibitors of farnesyltransferase
    deSolms, SJ
    Giuliani, EA
    Graham, SL
    Koblan, KS
    Kohl, NE
    Mosser, SD
    Oliff, AI
    Pompliano, DL
    Rands, E
    Scholz, TH
    Wiscount, CM
    Gibbs, JB
    Smith, RL
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (14) : 2651 - 2656
  • [7] DESOLMS SJ, UNPUB
  • [8] A MECHANISM FOR POSTTRANSLATIONAL MODIFICATIONS OF PROTEINS BY YEAST PROTEIN FARNESYLTRANSFERASE
    DOLENCE, JM
    POULTER, CD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (11) : 5008 - 5011
  • [9] Du W, 1999, CANCER RES, V59, P2059
  • [10] Protein farnesyltransferase: Structure and implications for substrate binding
    Dunten, P
    Kammlott, U
    Crowther, R
    Weber, D
    Palermo, R
    Birktoft, J
    [J]. BIOCHEMISTRY, 1998, 37 (22) : 7907 - 7912